Axon's Tau Vaccine Shows Promise in Phase II Alzheimer's Study

Austria’s AXON Neuroscience posted positive results from its Phase II Alzheimer’s disease trial assessing AADvac1, a tau vaccine under development to treat and prevent the disease.